Teos Therapeutics downgraded to Hold after belrestotug failure and GSK deal ending. Read my updated analysis on ITOS stock ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Fintel reports that on May 13, 2025, JP Morgan downgraded their outlook for iTeos Therapeutics (NasdaqGM:ITOS) from ...

Fintel reports that on May 14, 2025, Leerink Partners downgraded their outlook for iTeos Therapeutics (NasdaqGM:ITOS) from ...

Join Plus500 today and get up to $200 to start trading real futures. Practice with free paper trading, then jump into live ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

TerraVest Industries Inc (TVK.T) is expected to report for 2Q. United Homes Group Inc (UHG) is expected to report for 1Q. Valeura Energy Inc (PNWRF,VLE.T) is expected to report for 1Q. Vislink ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a ...

GSK plc with its development partner iTeos Therapeutics, Inc., has announced that it is ending the development programme for ...

Teos Therapeutics faces significant setbacks with the discontinuation of their TIGIT program and belrestotug, leaving them ...